4.7 Article

Cerebral blood flow predicts differential neurotransmitter activity

期刊

SCIENTIFIC REPORTS
卷 8, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-018-22444-0

关键词

-

资金

  1. Michael J. Fox Foundation for Parkinson's Research
  2. Abbvie
  3. Avid Radiopharmaceuticals
  4. Biogen Idec
  5. Briston-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. GlaxoSmithKline
  10. Lilly
  11. Lundbeck
  12. Merck
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Roche
  17. UCB
  18. MRC [G1002226] Funding Source: UKRI

向作者/读者索取更多资源

Application of metabolic magnetic resonance imaging measures such as cerebral blood flow in translational medicine is limited by the unknown link of observed alterations to specific neurophysiological processes. In particular, the sensitivity of cerebral blood flow to activity changes in specific neurotransmitter systems remains unclear. We address this question by probing cerebral blood flow in healthy volunteers using seven established drugs with known dopaminergic, serotonergic, glutamatergic and GABAergic mechanisms of action. We use a novel framework aimed at disentangling the observed effects to contribution from underlying neurotransmitter systems. We find for all evaluated compounds a reliable spatial link of respective cerebral blood flow changes with underlying neurotransmitter receptor densities corresponding to their primary mechanisms of action. The strength of these associations with receptor density is mediated by respective drug affinities. These findings suggest that cerebral blood flow is a sensitive brain-wide in-vivo assay of metabolic demands across a variety of neurotransmitter systems in humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据